Maurice Alston, DO
Cardiovascular Disease · Athens, TNNPI 1184999021
Payments from drug & device makers
Across 333 payments — averaging $90.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Penumbra, Inc.$6K
- Medtronic$3K
- Inari Medical, Inc.$2K
- Philips North America LLC$2K
- Boston Scientific$1K
- plus $5K from 21 others
What the payments were for
- Travel & lodging$19,57165%
- Food & beverage$10,51535%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 73 | $11,046 |
| Penumbra, Inc. | 19 | $5,527 |
| Medtronic(2 entities) | 22 | $2,704 |
| Inari Medical, Inc. | 9 | $2,372 |
| Philips North America LLC | 19 | $1,966 |
| Boston Scientific | 17 | $1,266 |
| Edwards Lifesciences | 12 | $1,081 |
| Cardiovascular Systems Inc. | 6 | $771 |
| Shockwave Medical, Inc | 8 | $460 |
| Pfizer | 27 | $423 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $415 |
| Novartis | 21 | $373 |
| Acist Medical Systems, Inc. | 3 | $322 |
| E.r. Squibb & Sons, L.L.C. | 22 | $294 |
| Boehringer Ingelheim | 12 | $200 |
| Novo Nordisk | 5 | $155 |
| AstraZeneca | 2 | $138 |
| Lantheus Medical Imaging, Inc. | 6 | $115 |
| Merck | 5 | $91 |
| Amgen | 5 | $87 |
| Scpharmaceuticals Inc. | 3 | $63 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| Johnson & Johnson | 3 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $44 |
| Baxter Healthcare | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$4,221
- Indigo System$3,061
- OPTIS$2,744
- FLOWTRIEVER CATHETER, S$2,203
- CT THROMBECTOMY SYSTEM KIT$2,203
- RUBY Coil$2,058
- SUPERA$1,373
- Micra$1,179
- US Und$1,118
- CoreValve Evolut$839
- Mitra Clip system$796
- Coronary Orbital Atherectomy System$560
- (7881) Ultrasound Und$372
- ROTABLATOR$340
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$305
- GENERAL VASCULAR ACCESS$213
- GENERAL ATHERECTOMY$192
- (BQ9) Coronary IVUS$173
- ESPRIT$156
- Smart Coil$143
How this compares
$30,095 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $158,898 |
| XareltoRivaroxaban | 64 | $61,970 |
| EntrestoSacubitril/Valsartan | 49 | $43,263 |
| JardianceEmpagliflozin | 27 | $21,570 |
| BrilintaTicagrelor | 24 | $21,075 |
| CorlanorIvabradine Hcl | 17 | $8,336 |
| Ranolazine ErRanolazine | 33 | $4,528 |
| Metoprolol Succinate | 86 | $1,271 |
| Atorvastatin Calcium | 90 | $1,090 |
| ClopidogrelClopidogrel Bisulfate | 93 | $1,073 |
| Amiodarone Hcl | 22 | $969 |
| Carvedilol | 119 | $768 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 93 | $760 |
| Bumetanide | 19 | $679 |
| Ezetimibe | 23 | $604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $423 | $158,898140 claims |
| Johnson & JohnsonXarelto | $49 | $61,97064 claims |
| NovartisEntresto | $373 | $43,26349 claims |
| Boehringer IngelheimJardiance | $200 | $21,57027 claims |
| AstraZenecaBrilinta | $138 | $21,07524 claims |
| AmgenCorlanor | $87 | $8,33617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Athens
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
- Joann LindenfeldNashville$2.2M
- Frank McGrewMemphis$2.1M
- Rebecca HungNashville$1.8M
- Mohsin AlhaddadJackson$1.8M
- Robert SmithBrentwood$1.3M
- Travis RichardsonNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.